Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 12/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390382 | 1.00 | GHSR (0.64) | GHSR | |
| SCHEMBL29414549 | 0.95 | GHSR (0.61) | GHSR | |
| SCHEMBL30276253 | 0.94 | GHSR (0.64) | GHSR | |
| SCHEMBL29551293 | 0.94 | GHSR (0.64) | GHSR | |
| SCHEMBL29754403 | 0.94 | GHSR (0.57) | GHSR | |
| SCHEMBL29366876 | 0.94 | GHSR (0.60) | GHSR | |
| SCHEMBL29507073 | 0.94 | GHSR (0.60) | GHSR | |
| SCHEMBL31632621 | 0.94 | GHSR (0.63) | GHSR | |
| SCHEMBL30276276 | 0.94 | GHSR (0.63) | GHSR | |
| SCHEMBL30490002 | 0.93 | GHSR (0.66) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000730-A1 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS | CAMURUS AB (SE) | 2026-01-01 | — | — | US | disclosed |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | CAMURUS AB (SE) | 2025-11-13 | — | — | US | disclosed |
| EP-4583873-A2 | GENETICALLY ENGINEERED HUMAN PITUITARY CORTICOTROPH TUMOR ORGANOIDS EXHIBIT DIVERGENT RESPONSES TO SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-112261874-B | Inhibition of fungal growth by manganese depletion | 科·汉森有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-120131956-A | Use of growth hormone inhibitors, and pharmaceutical compositions, formulations, and devices containing growth hormone inhibitors | 中山大学中山眼科中心 | 2025-06-13 | — | — | CN | disclosed |
| CN-114555817-B | Rhamnose polysaccharide | 敦提大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-114720356-B | Flow cytometry detection kit for advanced immune characterization of lung cancer and detection method thereof | 李太生 | 2025-05-13 | — | — | CN | disclosed |
| CN-113302207-B | Antibodies to CD38 and ICAM1 and uses thereof | 维尔托索宾科公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | BCN PEPTIDES, S.A. (ES) | 2025-05-13 | — | — | US | disclosed |
| CN-111886336-B | CASZ compositions and methods of use | 加利福尼亚大学董事会 | 2025-05-02 | — | — | CN | disclosed |
| CN-114269372-A | Use of chimeric antigen receptor T cells and NK cell inhibitors for the treatment of cancer | 克里斯珀医疗股份公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114258305-A | Type III NKT cells and related compositions and methods | 阿克索治疗公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114258401-A | Antibodies specific for CD38 and uses thereof | INSERM(法国国家健康医学研究院) | 2022-03-29 | — | — | CN | disclosed |
| CN-113980940-B | Method for improving catalytic efficiency of bifunctional cellulase, mutant, gene and application | 中国农业科学院北京畜牧兽医研究所 | 2022-03-25 | — | — | CN | disclosed |
| US-11261215-B2 | Somatostatin prodrugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-01 | — | — | US | disclosed |
| CN-112533936-B | Method for purifying peptide using sulfonic acid compound | 长濑产业株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-114072677-A | Reagents and methods for cancer detection, prognosis and therapy monitoring | 美国桑福德医疗集团 | 2022-02-18 | — | — | CN | disclosed |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | CAMURUS AB (SE) | 2022-02-08 | — | — | US | disclosed |
| CN-109311910-B | Tacrolimus conjugates, compositions thereof, and uses thereof | 杜兰教育基金委员会 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993543-A | Combination therapy with anti-CD 38 antibodies | 武田药品工业株式会社 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | PHOSPHO1, LIPA, ABHD16A | GHSR 2869/4885 |
| US-11261215-B2 | Somatostatin prodrugs | VIP, SSTR4, SSTR5 | GHSR 18/4885 |
| US-20260000730-A1 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS | SSTR1, SSTR3, SSTR5 | GHSR 35/4885 |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | PHOSPHO1, LIPA, ABHD16A | GHSR 2892/4885 |
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | GHSR, GIPR, GHRHR | GHSR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.